Urtasun R C, Belch A, Bodnar D
Int J Radiat Oncol Biol Phys. 1983 Oct;9(10):1575-8. doi: 10.1016/0360-3016(83)90332-2.
In a previously published paper, the results of a preliminary clinical trial comparing systemic radiation (upper and lower hemibody technique) versus systemic chemotherapy in the management of all stages of small cell lung cancer (SCLC), suggested that hemibody radiation (HBI) was as efficient as systemic chemotherapy, particularly for patients with early disease. We are now presenting the final results of the above trial. The two year survival has shown that as many patients in the HBI as in the chemotherapy arm have reached this endpoint. However, there is a difference in favor of chemotherapy on both the median and one year survival for those patients with advanced stages. Therefore, as of June 1981, we have initiated a study incorporating HBI as a consolidating-maintenance agent for patients with all stages of the disease who have received a 3 1/2 months induction systemic chemotherapy plus local chest irradiation. Up to date, 65 patients have been entered and our median survival for those who received the complete treatment is 62.5 weeks.
在之前发表的一篇论文中，一项比较全身放疗（上下半身技术）与全身化疗治疗各期小细胞肺癌（SCLC）的初步临床试验结果表明，半身放疗（HBI）与全身化疗效果相当，尤其是对于早期疾病患者。我们现在公布上述试验的最终结果。两年生存率显示，接受HBI治疗的患者和接受化疗的患者达到这一终点的人数相同。然而，对于晚期患者，化疗在中位生存期和一年生存率方面更具优势。因此，截至1981年6月，我们启动了一项研究，将HBI作为巩固维持药物，用于所有分期疾病且已接受3个半月诱导全身化疗加局部胸部放疗的患者。到目前为止，已有65名患者入组，接受完整治疗的患者的中位生存期为62.5周。
